Methotrexat Accord

Methotrexate, the active ingredient in Methotrexat Accord, is an antimetabolite presented as a sterile injectable for intraarterial, intramuscular, and intrathecal use. It interferes with DNA synthesis and is employed in the treatment of autoimmune disorders and selected malignancies in adults and children.

GNH USA supplies Methotrexat Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and clinical use. Our distribution network ensures timely delivery across multiple continents.

Methotrexate acts as a folate antagonist and is used across several autoimmune and oncologic disease pathways. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: diminishes skin plaque formation and improves lesion clearance. - Acute lymphoblastic leukemia: induces remission by inhibiting malignant lymphoblast proliferation. - Non‑Hodgkin lymphoma: contributes to tumor control through cytotoxic activity. - Osteosarcoma: enhances chemotherapy effectiveness by disrupting tumor cell DNA synthesis.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting - Fatigue - Mucositis (mouth sores) - Elevated liver enzymes

Serious or Rare Side Effects: - Bone marrow suppression with risk of infection - Pulmonary toxicity (pneumonitis) - Severe hepatotoxicity or renal failure

When using Methotrexat Accord, several safety measures should be observed to minimize risk. - Pregnancy contraindication: avoid use in pregnancy due to teratogenic risk (Category X). - Renal function monitoring: assess creatinine clearance before and during therapy. - Hepatic function monitoring: perform baseline and periodic liver enzyme tests. - Hematologic monitoring: conduct regular complete blood counts to detect marrow suppression. - Concomitant drug review: avoid concurrent folate antagonists and adjust NSAID use. - Store at room temperature: keep in original container, protect from moisture and light.

Methotrexate has notable interactions that may require avoidance or close monitoring.

Major Interactions (Avoid): - Other folate antagonists (e.g., trimethoprim‑sulfamethoxazole): increase toxicity. - High‑dose NSAIDs: may reduce renal clearance and raise serum levels. - Live vaccines: risk of severe infection due to immunosuppression. - Proton pump inhibitors (e.g., omeprazole): can elevate methotrexate concentrations.

Moderate Interactions (Monitor Closely): - Azathioprine or other myelosuppressive agents: additive bone‑marrow suppression. - Oral contraceptives: may decrease methotrexate efficacy. - Penicillins (e.g., ampicillin): may reduce renal elimination of methotrexate.